blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3718572

EP3718572 - NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD AND USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.06.2025
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  27.06.2024
FormerGrant of patent is intended
Status updated on  12.03.2024
FormerExamination is in progress
Status updated on  10.02.2023
FormerRequest for examination was made
Status updated on  04.09.2020
FormerThe international publication has been made
Status updated on  08.06.2019
Most recent event   Tooltip13.03.2026Lapse of the patent in a contracting state
New state(s): HU		published on 15.04.2026 [2026/16]
Applicant(s)For all designated states
Suzhou Ribo Life Science Co., Ltd.
No. 168 Yuanfeng Road
Yushan Town
Kunshan, Jiangsu 215300 / CN
[2020/41]
Inventor(s)01 / ZHANG, Hongyan
No.168 Yuanfeng Road
Yushan Town
Kunshan
Suzhou Jiangsu 215300 / CN
02 / GAO, Shan
No.168 Yuanfeng Road
Yushan Town
Kunshan
Suzhou Jiangsu 215300 / CN
03 / KANG, Daiwu
No.168 Yuanfeng Road
Yushan Town
Kunshan
Suzhou Jiangsu 215300 / CN
 [2020/41]
Representative(s)SSM Sandmair
Patentanwälte Rechtsanwalt
Partnerschaft mbB
Joseph-Wild-Straße 20
81829 München / DE
[2020/41]
Application number, filing date18883362.829.11.2018
[2020/41]
WO2018CN118300
Priority number, dateCN20171124937801.12.2017         Original published format: CN201711249378
CN20171147893329.12.2017         Original published format: CN201711478933
[2020/41]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019105435
Date:06.06.2019
Language:ZH
[2019/23]
Type: A1 Application with search report 
No.:EP3718572
Date:07.10.2020
Language:EN
[2020/41]
Type: B1 Patent specification 
No.:EP3718572
Date:31.07.2024
Language:EN
[2024/31]
Search report(s)International search report - published on:CN06.06.2019
(Supplementary) European search report - dispatched on:EP09.08.2021
ClassificationIPC:C12N15/113, A61K48/00, A61K31/713, A61P31/20
[2021/36]
CPC:
C12N15/1131 (EP,US); A61K31/713 (EP,US); A61P31/20 (EP,US);
C12N2310/14 (EP,US); C12N2310/315 (EP,US); C12N2310/321 (EP,US);
C12N2310/322 (EP,US); C12N2310/344 (US); C12N2310/346 (EP);
C12N2310/351 (EP,US); C12N2310/3515 (EP); C12N2320/32 (US) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP);
C12N2310/322, C12N2310/3533 (EP)
Former IPC [2020/41]A61K48/00, A61K31/713, A61P31/20, C12N15/113
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/41]  
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:NUKLEINSÄURE, ZUSAMMENSETZUNG UND KONJUGAT MIT NUKLEINSÄURE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG[2020/41]
English:NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD AND USE[2020/41]
French:ACIDE NUCLÉIQUE, COMPOSITION ET CONJUGUÉ CONTENANT UN ACIDE NUCLÉIQUE, PROCÉDÉ DE PRÉPARATION ET UTILISATION[2020/41]
Entry into regional phase04.06.2020Translation filed 
04.06.2020National basic fee paid 
04.06.2020Search fee paid 
04.06.2020Designation fee(s) paid 
04.06.2020Examination fee paid 
Examination procedure04.06.2020Examination requested  [2020/41]
25.02.2022Amendment by applicant (claims and/or description)
14.02.2023Despatch of a communication from the examining division (Time limit: M04)
14.06.2023Reply to a communication from the examining division
31.08.2023Despatch of a communication from the examining division (Time limit: M04)
04.12.2023Reply to a communication from the examining division
13.03.2024Communication of intention to grant the patent
19.06.2024Fee for grant paid
19.06.2024Fee for publishing/printing paid
19.06.2024Receipt of the translation of the claim(s)
Opposition(s)01.05.2025No opposition filed within time limit [2025/28]
Fees paidRenewal fee
04.06.2020Renewal fee patent year 03
24.11.2021Renewal fee patent year 04
24.11.2022Renewal fee patent year 05
24.11.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.11.2018
CZ31.07.2024
ES31.07.2024
HR31.07.2024
MC31.07.2024
PL31.07.2024
SK31.07.2024
SM31.07.2024
NO31.10.2024
RS31.10.2024
GR01.11.2024
GB29.11.2024
IE29.11.2024
CH30.11.2024
IS30.11.2024
[2026/16]
Former [2025/48]CZ31.07.2024
ES31.07.2024
HR31.07.2024
MC31.07.2024
PL31.07.2024
SK31.07.2024
SM31.07.2024
NO31.10.2024
RS31.10.2024
GR01.11.2024
GB29.11.2024
IE29.11.2024
CH30.11.2024
IS30.11.2024
Former [2025/47]CZ31.07.2024
ES31.07.2024
HR31.07.2024
MC31.07.2024
PL31.07.2024
SK31.07.2024
SM31.07.2024
NO31.10.2024
RS31.10.2024
GR01.11.2024
GB29.11.2024
CH30.11.2024
IS30.11.2024
Former [2025/35]CZ31.07.2024
ES31.07.2024
HR31.07.2024
MC31.07.2024
PL31.07.2024
SK31.07.2024
SM31.07.2024
NO31.10.2024
RS31.10.2024
GR01.11.2024
CH30.11.2024
IS30.11.2024
Former [2025/33]CZ31.07.2024
ES31.07.2024
HR31.07.2024
MC31.07.2024
PL31.07.2024
SK31.07.2024
SM31.07.2024
NO31.10.2024
RS31.10.2024
GR01.11.2024
IS30.11.2024
Former [2025/23]CZ31.07.2024
ES31.07.2024
HR31.07.2024
PL31.07.2024
SK31.07.2024
SM31.07.2024
NO31.10.2024
RS31.10.2024
GR01.11.2024
IS30.11.2024
Former [2025/21]ES31.07.2024
HR31.07.2024
PL31.07.2024
SM31.07.2024
NO31.10.2024
RS31.10.2024
GR01.11.2024
IS30.11.2024
Former [2025/10]ES31.07.2024
HR31.07.2024
PL31.07.2024
NO31.10.2024
RS31.10.2024
GR01.11.2024
IS30.11.2024
Former [2025/09]PL31.07.2024
NO31.10.2024
GR01.11.2024
IS30.11.2024
Former [2025/08]PL31.07.2024
NO31.10.2024
GR01.11.2024
Documents cited:Search[A] WO2017015175  (ARCTURUS THERAPEUTICS INC et al.) [A] 1 * sequence 17 *
 [I] US2003206887  (MORRISSEY DAVID et al.) [I] 1-25 * the whole document *
 [I] WO2004078181  (CAPITAL BIOCHIP CO LTD et al.) [I] 1-25 * the whole document *
 [I] WO2012024170  (MERCK SHARP & DOHME et al.) [I] 1-25 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.